Randomized Dose-Ranging Study of the 14-Day Early Bactericidal Activity of Bedaquiline (TMC207) in Patients with Sputum Microscopy Smear-Positive Pulmonary Tuberculosis

H. Diacon, Andreas; Dawson, Rodney; von Groote-Bidlingmaier, Florian; Symons, Gregory; Venter, Amour; R. Donald, Peter; Conradie, Almari; Erondu, Ngozi; M. Ginsberg, Ann; Egizi, Erica; Winter, Helen; Becker, Piet; M. Mendel, Carl

doi:10.1128/aac.02243-12

Public

Randomized Dose-Ranging Study of the 14-Day Early Bactericidal Activity of Bedaquiline (TMC207) in Patients with Sputum Microscopy Smear-Positive Pulmonary Tuberculosis

Published in Antimicrobial Agents and Chemotherapy • Mar 5, 2013

Authors:

Andreas H. Diacon

Rodney Dawson

Florian von Groote-Bidlingmaier

Abstract

Bedaquiline is a new antituberculosis agent targeting ATP synthase. This randomized, double-blinded study enrolling 68 sputum smear-positive pulmonary tuberculosis patients evaluated the 14-day early bactericidal activity of daily doses of 100 mg, 200 mg, 300 mg, and 400 mg bedaquiline, preceded by ...

Subject

Bedaquiline

Sputum

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!